Published in J Clin Endocrinol Metab on February 15, 2010
Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol (2010) 2.06
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res (2011) 2.00
Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone (2011) 1.96
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res (2011) 1.95
Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab (2010) 1.87
The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84
The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One (2012) 1.76
Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporos Int (2011) 1.61
Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res (2011) 1.53
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int (2011) 1.23
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol (2013) 1.23
The clinical utility of bone marker measurements in osteoporosis. J Transl Med (2013) 1.21
Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone (2011) 1.19
Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol (2015) 1.15
Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int (2012) 1.13
Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest (2011) 1.12
Osteocyte-driven bone remodeling. Calcif Tissue Int (2013) 1.08
Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab (2012) 1.08
Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res (2012) 1.07
Postmenopausal osteoporosis: the role of immune system cells. Clin Dev Immunol (2013) 1.04
The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol (2013) 1.03
Effects of PTH on osteocyte function. Bone (2012) 1.03
Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology (2011) 1.02
Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int (2011) 1.00
Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab (2011) 0.99
Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab (2011) 0.96
Osteoporosis and obesity: Role of Wnt pathway in human and murine models. World J Orthop (2014) 0.96
Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int (2011) 0.91
Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos Int (2014) 0.90
Circulating sclerostin is elevated in short-term and reduced in long-term SCI. Bone (2012) 0.90
Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. J Clin Endocrinol Metab (2013) 0.88
The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b. J Bone Miner Res (2014) 0.88
Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes. Osteoporos Int (2013) 0.87
Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res (2013) 0.87
Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation. J Cell Physiol (2012) 0.86
Anorexia nervosa, obesity and bone metabolism. Pediatr Endocrinol Rev (2013) 0.86
Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone (2012) 0.85
Serum estradiol levels are inversely associated with cortical porosity in older men. J Clin Endocrinol Metab (2014) 0.85
Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation? Osteoporos Int (2012) 0.84
Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner Res (2013) 0.83
Serum sclerostin levels in healthy men over 50 years of age. J Bone Miner Metab (2013) 0.81
Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats. Osteoporos Int (2014) 0.81
Effect of liver dysfunction on circulating sclerostin. J Bone Miner Metab (2013) 0.80
Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int (2015) 0.80
Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab (2013) 0.80
Changes in Dickkopf-1 (DKK1) and Sclerostin following a Loading Dose of Vitamin D 2 (300,000 IU). J Osteoporos (2014) 0.80
The osteocyte plays multiple roles in bone remodeling and mineral homeostasis. Med Mol Morphol (2015) 0.79
T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone. Ann N Y Acad Sci (2015) 0.79
Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. Int J Endocrinol (2014) 0.79
Sclerostin Immunoreactivity Increases in Cortical Bone Osteocytes and Decreases in Articular Cartilage Chondrocytes in Aging Mice. J Histochem Cytochem (2015) 0.78
Sclerostin. J Osteoporos (2010) 0.78
Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab (Seoul) (2014) 0.77
Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression. Ann N Y Acad Sci (2015) 0.77
Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. J Cancer Res Clin Oncol (2014) 0.76
The effect of renal dysfunction on circulating sclerostin level in patients with type 2 diabetes. Int J Endocrinol (2014) 0.76
Oxytocin and bone. Am J Physiol Regul Integr Comp Physiol (2014) 0.76
Hormonal and systemic regulation of sclerostin. Bone (2016) 0.75
Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients. Spinal Cord (2015) 0.75
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism. BMC Nephrol (2016) 0.75
Sclerostin as a novel marker of bone turnover in athletes. Biol Sport (2016) 0.75
Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry. J Bone Metab (2016) 0.75
Osteocytes and Skeletal Pathophysiology. Curr Mol Biol Rep (2015) 0.75
The effect of single extremity-vibration on the serum sclerostin level. J Phys Ther Sci (2015) 0.75
Serum sclerostin is decreased following vitamin D treatment in young vitamin D-deficient female adults. Rheumatol Int (2015) 0.75
Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse. Bone (2016) 0.75
Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level. Osteoporos Int (2014) 0.75
Changes in expression of Wnt signaling pathway inhibitors dickkopf-1 and sclerostin before and after total joint arthroplasty. Medicine (Baltimore) (2017) 0.75
The Utility of Biomarkers in Osteoporosis Management. Mol Diagn Ther (2017) 0.75
Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS One (2017) 0.75
[Biochemical markers of bone metabolism and their importance]. Z Rheumatol (2016) 0.75
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell (2005) 8.16
LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development (2004) 6.21
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet (2001) 5.72
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem (2005) 5.33
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res (2008) 4.82
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res (2009) 4.40
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J (2003) 4.32
A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res (1998) 4.24
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem (2005) 4.13
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet (2002) 4.00
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med (2004) 3.88
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res (2003) 3.32
SOST is a target gene for PTH in bone. Bone (2005) 2.94
Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res (2006) 2.61
Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci (2006) 2.18
Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone (2004) 1.71
Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. Neurology (1983) 1.47
The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones (Athens) (2007) 1.27
Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep (2007) 1.24
The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol (2007) 1.23
Trabecular bone remodeling and balance in primary hyperparathyroidism. Bone (1986) 1.10
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med (2005) 2.21
Identification of multiple osteoclast precursor populations in murine bone marrow. J Bone Miner Res (2005) 1.75
Homocysteine and osteoporotic fractures--culprit or bystander? N Engl J Med (2004) 1.74
Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet (2002) 1.54
Comparison of the effects of calcium loading with calcium citrate or calcium carbonate on bone turnover in postmenopausal women. Osteoporos Int (2004) 1.51
Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res (2003) 1.39
Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab (2010) 1.28
Fluid flow induction of cyclo-oxygenase 2 gene expression in osteoblasts is dependent on an extracellular signal-regulated kinase signaling pathway. J Bone Miner Res (2002) 1.28
T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res (2006) 1.26
Ebf1-dependent control of the osteoblast and adipocyte lineages. Bone (2008) 1.23
Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res (2002) 1.10
Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res (2006) 1.06
1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. J Immunol (2002) 1.05
Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. Mol Aspects Med (2005) 1.03
RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone (2005) 1.02
Pax5-deficient mice exhibit early onset osteopenia with increased osteoclast progenitors. J Immunol (2004) 1.02
Identification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery. J Bone Miner Res (2013) 1.02
Stimulation of cAMP production and cyclooxygenase-2 by prostaglandin E(2) and selective prostaglandin receptor agonists in murine osteoblastic cells. Bone (2004) 1.00
Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrow. J Bone Miner Res (2011) 0.95
Osteoblast-specific overexpression of human interleukin-7 rescues the bone mass phenotype of interleukin-7-deficient female mice. J Bone Miner Res (2012) 0.95
How B cells influence bone biology in health and disease. Bone (2010) 0.94
Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor. J Bone Miner Res (2004) 0.93
The origins of osteoclasts. Curr Opin Rheumatol (2004) 0.90
Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology (2003) 0.90
The surface antigen CD45R identifies a population of estrogen-regulated murine marrow cells that contain osteoclast precursors. Bone (2003) 0.87
Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling. J Bone Miner Res (2013) 0.87
Extracellular calcium is a potent inducer of cyclo-oxygenase-2 in murine osteoblasts through an ERK signaling pathway. J Bone Miner Res (2003) 0.87
Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J Immunol (2003) 0.86
Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase. Cell Tissue Res (2004) 0.86
Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells. Prostaglandins Other Lipid Mediat (2006) 0.86
Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. 2002. J Bone Miner Res (2005) 0.86
Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine. Am J Pathol (2010) 0.85
Extracellular calcium induces COX-2 in osteoblasts via a PKA pathway. Biochem Biophys Res Commun (2004) 0.84
Effects of prostaglandin E2 on bone in mice in vivo. Prostaglandins Other Lipid Mediat (2009) 0.83
Effect of deletion of the prostaglandin EP4 receptor on stimulation of calcium release from cultured mouse calvariae: impaired responsiveness in heterozygotes. Prostaglandins Other Lipid Mediat (2005) 0.83
Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice. Bone (2010) 0.82
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg (2008) 0.81
Effects of smoking cessation or reduction on hormone profiles and bone turnover in postmenopausal women. Nicotine Tob Res (2002) 0.81
The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab (2002) 0.81
Immunologic regulation of bone development. Adv Exp Med Biol (2007) 0.81
Loss of Cbl-PI3K interaction enhances osteoclast survival due to p21-Ras mediated PI3K activation independent of Cbl-b. J Cell Biochem (2014) 0.79
B lymphocytes and the skeleton. Ann N Y Acad Sci (2007) 0.79
Mechanisms of bone remodeling: implications for clinical practice. J Reprod Med (2002) 0.79
Altered hematopoietic stem cell and osteoclast precursor frequency in cathepsin K null mice. J Cell Biochem (2014) 0.78
Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. Prostaglandins Other Lipid Mediat (2002) 0.77
Bone morphogenetic protein 2 enhances PGE(2)-stimulated osteoclast formation in murine bone marrow cultures. Prostaglandins Other Lipid Mediat (2009) 0.77
Challenges in science and academic-industry interactions. J Bone Miner Res (2007) 0.75
Changes in urinary excretion of helical peptide during therapy for osteoporosis in older adults. Clin Chem (2004) 0.75
Osteoporosis panel summary. J Bone Miner Res (2003) 0.75
Prevention and treatment of osteoporosis. Clin Cornerstone (2002) 0.75